Company Encyclopedia
View More
name
Nutriband
NTRB.US
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products.
4.673 T
NTRB.USMarket value -Rank by Market Cap -/-

Financial Score

23/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking92/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-368.44%E
    • Profit Margin-560.85%E
    • Gross Margin19.80%D
  • Growth ScoreC
    • Revenue YoY12.69%B
    • Net Profit YoY-405.21%E
    • Total Assets YoY-32.88%E
    • Net Assets YoY-32.79%E
  • Cash ScoreC
    • Cash Flow Margin-6.59%D
    • OCF YoY12.69%B
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreA
    • Gearing Ratio10.34%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Nutriband Inc. Announces Date for Upcoming Annual Meeting of Stockholders

    Nutriband Inc. will hold its Annual Meeting of Stockholders in Orlando, Florida, on January 24, 2026. Shareholders will vote on the election of seven directors to the Board of Directors. This announcement was published via EDGAR by Nutriband Inc. on December 19, 2025.

    Reuters·
    US
    NTRB
    -2.45%
    Reuters·
    US
    NTRB
    -2.45%

    Nutriband Signs LOI to Explore Quantum-AI Collaboration with Qvanta Group

    Nutriband Inc. has signed a non-binding Letter of Intent with Qvanta Group to explore collaboration in advanced technology solutions. The focus is on secure AI and analytics for pharmaceutical data, cybersecurity for abuse-deterrent technologies, and quantum-ready infrastructure. This exploratory agreement does not establish a formal partnership, with future collaboration subject to further review and agreements.

    Reuters·
    US
    NTRB
    -2.45%
    Reuters·
    US
    NTRB
    -2.45%

    Nutriband Partners with Kindeva to Develop Abuse-Deterrent Fentanyl Patch

    Nutriband Inc. has partnered with Kindeva to develop AVERSA™ Fentanyl, an abuse-deterrent transdermal fentanyl patch. This collaboration combines Nutriband’s AVERSA™ technology with Kindeva’s FDA-approved fentanyl patch to improve safety and deter misuse while ensuring effective pain management for patients.

    Reuters·
    US
    NTRB
    -2.45%
    Reuters·
    US
    NTRB
    -2.45%

    Nutriband Inc. to Present at Noble Capital Markets Emerging Growth Equity Conference

    Nutriband Inc. (NASDAQ: NTRB, NTRBW) will present at NobleCon21, the Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference, on December 3rd, 2025, at 9:30 AM EST. The event will be held at Florida Atlantic University’s Executive Education Complex in Boca Raton, Florida. Investors and guests can attend at a discounted rate using the code NTRBNOBLECON, and a webcast will be available the next day on the Noble Conference website and Channelchek.com.

    Reuters·
    US
    NTRB
    -2.45%
    Reuters·
    US
    NTRB
    -2.45%

    Nutriband Advances with FDA on Fentanyl Patch

    Nutriband Inc. has successfully met with the US FDA regarding its AVERSA™ FENTANYL patch, aimed at addressing fentanyl patch abuse. The meeting provided crucial feedback for their development program as they prepare for an IND filing. Projected US sales could reach $80 million to $200 million annually. Analyst ratings for NTRB stock are mixed, with a Buy rating and a $15.00 price target, while Spark's AI Analyst rates it as Neutral due to financial challenges. Nutriband focuses on developing transdermal products to prevent drug abuse.

    Tip Ranks·
    US
    NTRB
    -2.45%
    Tip Ranks·
    US
    NTRB
    -2.45%
    © 2025 Longbridge｜Disclaimer